Nanobiotix Reports Share Capital and Voting Rights as of August 31, 2026
Biotechnology company Nanobiotix announced its share capital and voting rights as of August 31, 2026. The company reported 50,941,528 outstanding shares and 54,679,128 exercisable voting rights.
Nanobiotix, a late-stage clinical biotechnology firm, has disclosed its share capital and total voting rights as of August 31, 2026. The company stated it had 50,941,528 shares outstanding and 54,679,128 exercisable voting rights. The total number of theoretical voting rights, including those with suspended voting rights, stood at 54,701,246.
These figures are crucial for shareholders and the market, as they represent the company's voting structure and influence shareholder decisions at general meetings. Nanobiotix focuses on physics-based therapeutic approaches in oncology, aiming to improve treatment outcomes for cancer patients.
Founded in 2003 and headquartered in Paris, France, Nanobiotix is listed on both Euronext Paris and the Nasdaq Global Select Market. The company operates in the biotechnology sector, specializing in developing disruptive treatments.
The disclosure adheres to French commercial law and the regulations of the French Financial Markets Authority (AMF). This information is vital for investors tracking the company's financial standing and ownership structure.